Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Amortization of Deferred Charges (2016 - 2024)

Historic Amortization of Deferred Charges for Ernexa Therapeutics (ERNA) over the last 8 years, with Q4 2024 value amounting to $3.1 million.

  • Ernexa Therapeutics' Amortization of Deferred Charges rose 113944.22% to $3.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.3 million, marking a year-over-year increase of 197865.61%. This contributed to the annual value of $5.3 million for FY2024, which is 163564.36% up from last year.
  • Per Ernexa Therapeutics' latest filing, its Amortization of Deferred Charges stood at $3.1 million for Q4 2024, which was up 113944.22% from $1.2 million recorded in Q3 2024.
  • Over the past 5 years, Ernexa Therapeutics' Amortization of Deferred Charges peaked at $3.1 million during Q4 2024, and registered a low of $2000.0 during Q4 2020.
  • Its 3-year average for Amortization of Deferred Charges is $787857.1, with a median of $445000.0 in 2024.
  • In the last 5 years, Ernexa Therapeutics' Amortization of Deferred Charges changed by 0.0% in 2020 and then skyrocketed by 113944.22% in 2024.
  • Quarter analysis of 3 years shows Ernexa Therapeutics' Amortization of Deferred Charges stood at $2000.0 in 2020, then surged by 12450.0% to $251000.0 in 2023, then skyrocketed by 1139.44% to $3.1 million in 2024.
  • Its last three reported values are $3.1 million in Q4 2024, $1.2 million for Q3 2024, and $474000.0 during Q2 2024.